Your browser doesn't support javascript.
loading
Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?
Ko, Heidi; Previs, Rebecca A; Strickland, Kyle C; Klein, Jonathan; Caveney, Brian; Chiruzzi, Chiara; Eisenberg, Marcia; Severson, Eric A; Ramkissoon, Shakti; Saini, Kamal S.
Affiliation
  • Ko H; Labcorp Oncology, Durham, NC, 27560, USA. Heidi.Ko@labcorp.com.
  • Previs RA; Labcorp Oncology, Durham, NC, 27560, USA.
  • Strickland KC; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC, USA.
  • Klein J; Labcorp Oncology, Durham, NC, 27560, USA.
  • Caveney B; Department of Pathology, Duke University Medical Center, Duke Cancer Institute, Durham, NC, 27710, USA.
  • Chiruzzi C; Labcorp Oncology, Durham, NC, 27560, USA.
  • Eisenberg M; Labcorp Oncology, Durham, NC, 27560, USA.
  • Severson EA; Fortrea Inc, Durham, NC, USA.
  • Ramkissoon S; Labcorp Oncology, Durham, NC, 27560, USA.
  • Saini KS; Labcorp Oncology, Durham, NC, 27560, USA.
Oncol Ther ; 12(1): 13-17, 2024 Mar.
Article in En | MEDLINE | ID: mdl-37962832
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Oncol Ther Year: 2024 Document type: Article Affiliation country: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Oncol Ther Year: 2024 Document type: Article Affiliation country: Estados Unidos